Physician profile
Hans E Schuller
NPI 1407857568
$10,064.63
in general payments reported to CMS, 2019-2025
42 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,903 · 2020: $1,817 · 2021: $2,037 · 2022: $1,811 · 2023: $1,463 · 2024: $1,033.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,496.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,495.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,927.51 | 2019-2024 | Trelegy Ellipta, Arexvy, Nucala |
| Astrazeneca Pharmaceuticals LP | $1,619.31 | 2019-2024 | Breztri, Fasenra, Airsupra |
| Grifols USA, LLC | $831.38 | 2019-2024 | Prolastin-C Liquid |
| Boehringer Ingelheim Pharmaceuticals, INC. | $600.40 | 2019-2023 | Synjardy, Jardiance |
| Mylan Specialty L.P. | $551.35 | 2019-2024 | Yupelri, Yupelri |
| Insmed, INC. | $417.78 | 2019-2023 | Arikayce |
| Jazz Pharmaceuticals INC. | $356.80 | 2019-2022 | |
| Amgen INC. | $245.73 | 2019-2024 | Evenity, Prolia, Repatha |
| Amneal Pharmaceuticals LLC | $226.50 | 2019-2024 | Unithroid |
| Axsome Therapeutics, INC. | $206.69 | 2022-2024 | Sunosi |
| Kowa Pharmaceuticals America, INC. | $190.70 | 2019-2022 | |
| Lifescan, INC. | $188.73 | 2019-2022 | |
| Abbott Laboratories | $180.14 | 2019-2022 | |
| Lilly USA, LLC | $179.56 | 2022-2024 | Jardiance, Lyumjev |
| Novo Nordisk INC | $177.47 | 2021-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hans Schuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.